Combined Chemoradiotherapy-induced Weight Loss Decreases Survival in Locally Advanced Non-small Cell Lung Cancer Patients

联合放化疗引起的体重减轻会降低局部晚期非小细胞肺癌患者的生存率

阅读:1

Abstract

BACKGROUND/AIM: The aim of the study was to investigate the prognostic impact and predictors of weight loss during definitive radiotherapy in non-small cell lung cancer (NSCLC) patients. PATIENTS AND METHODS: A total of 125 NSCLC patients (2003-2016) who had received definitive radiotherapy were included in the study. Multivariate analyses were performed to estimate prognostic values. Predictors for weight loss were analyzed. RESULTS: The median survival of patients with weight loss (>5%) during radiotherapy and for those without any significant weight loss was 15.6 and 33 months, respectively (p=0.015). Non-intensity modulated radiotherapy (IMRT) technique was the only factor associated with weight loss (p=0.039). Weight loss was a poor prognostic factor for overall survival (OS) (hazard ratio [HR] 2.072, p=0.018), and IMRT was a favorable prognostic factor (HR=0.192, p=0.029). CONCLUSION: During definitive radiotherapy, weight loss of >5% resulted in decreased OS rate in locally advanced NSCLC. IMRT might increase OS rate by minimizing weight loss.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。